Introduction: A USP citation in a drug filing sets a specific release standard, so QA teams need COA wording and batch records that match the named monograph exactly.
When a supplier description says "USP grade titanium dioxide," that phrase has to survive contact with the filing itself. The formulation cites a compendial monograph. The reviewer asks for the certificate showing the batch was released against that monograph. Someone on the quality team then has to decide whether the paper in hand answers the question or just restates the grade name. Those three moving parts — grade language, COA release statements, and batch records — decide whether a filing moves forward smoothly or circles back with follow-up questions weeks later.
"USP grade" is shorthand for one thing: the material was tested and released against the titanium dioxide monograph in the United States Pharmacopeia. Once a filing cites that monograph, the monograph does the work. It defines identification, assay, and the physical and impurity tests the batch has to pass, along with the acceptance criteria for each one. The grade phrase on a product description is a pointer to that document. The release statement on a certificate is the evidence that a particular batch actually met it, and that distinction is what QA reviewers are trained to look for first. In the US market, titanium dioxide also sits inside the color additive provisions at 21 CFR 73.575, which set the specification background for its use in drug products. QA and regulatory readers usually hold both threads at once: the compendial monograph for excipient release, and the regulatory use provision for the application. They answer different questions, and a filing package works best when both line up with what the formulation declares. That is why a certificate that quotes "USP grade" without naming the monograph underneath it reads thin to an experienced reviewer. The same logic applies in other markets, with one practical twist: monographs are not identical across pharmacopoeias. USP, EP, BP, JP, and ChP each describe titanium dioxide with their own test set and limits, and the acceptance ranges are not interchangeable word for word. A batch released against ChP is documented against ChP. If the target filing names USP, request release matched to USP and have the supplier state that match in writing. Teint Pharmaceutical produces pharmaceutical grade titanium dioxide (CI Pigment White 6, PW6) under GMP controls and handles release against USP, EP, BP, JP, and ChP as separate, customer-named targets — the way filing teams actually work.
The certificate of analysis is where the mapping either happens or falls apart. IPEC guidance on certificates of analysis treats the COA as a release document tied to a defined specification, not a general product summary. Three things make that link readable for a reviewer in under five minutes.
Alongside the certificate, QA teams usually ask for the elemental impurity assessment carried out under ICH Q3D, since titanium dioxide is an inorganic excipient and that risk assessment forms part of the filing package in most regulated markets. Ask for the assessment for the grade and route of administration in scope, plus a specimen COA for the exact grade before the first order goes out.
Batch records and DMFs get requested in the same conversation and then travel in opposite directions. A batch record is production evidence. It shows the batch was manufactured and tested according to written procedures, with the checks, yields, and test data recorded at the time of manufacture. QA teams review it during a supplier audit, and what normally enters a customer file or a filing is a batch record summary or a certificate of release tied to a lot number, not the full internal record. A DMF is a confidential submission. The holder files manufacturing information with the agency, and a customer's application references that file only after the holder authorizes it. The FDA's DMF guidance describes that authorization route and the confidentiality it protects. So the two requests are different in kind. Batch records answer "was this lot made and released consistently?" A DMF answers "can my application reference confidential manufacturing information that has already been filed?" One is a quality document you read; the other is a regulatory channel the holder controls. That distinction shapes how a conversation with a pharmaceutical excipients supplier should open. Say early which pharmacopoeia the filing cites, which market the application targets, and whether the filing route depends on a DMF or a CEP. Where those routes are in scope, they need to be settled long before a submission date, not during sample evaluation. Teint's disclosed documentation covers pharmacopoeia-matched release and batch quality records; if your filing depends on a DMF or CEP, raise it in the first technical exchange so both sides know the regulatory path being used.
The decision comes down to one match: the monograph named in your filing and the release statement on the batch you intend to use. Read the certificate for the named pharmacopoeia, the batch-specific results, the ICH Q3D assessment, and the document control details; then separate what you read (batch records) from what the agency holds (confidential filings). When you contact Teint Pharmaceutical, send the target pharmacopoeia, the filing route, and the test list from your specification. Ask for a specimen COA for the grade, the elemental impurity assessment, the batch record scope, and a sample for laboratory qualification so the filing package is built on documents you have already reviewed.
A: It means the batch was tested and released against the titanium dioxide monograph in the United States Pharmacopeia, with results recorded for that batch. For a filing, the certificate should name the USP monograph, list batch-specific results against the monograph's tests, and be supported by an ICH Q3D elemental impurity assessment when the route of administration requires one.
A: The release statement should name the monograph the batch was released against — USP, EP, BP, JP, or ChP — and reference the specification used, with results, methods, and limits tied to a lot number. If your filing cites a different pharmacopoeia than the one on the certificate, request a release statement re-issued against the monograph your filing names.
A: Ask directly whether a DMF exists for the specific grade, who holds the file, whether letters of authorization are issued, and how that route pairs with the pharmacopoeia release you need. Keep that discussion separate from the batch record request, since one is a confidential filing channel and the other is quality documentation you review yourself.
CFR - Code of Federal Regulations Title 21
International Pharmaceutical Excipients Council of the Americas
Drug Master Files Guidance for Industry (FDA)